Independent online cancer second opinion for patients in India
For patients and families in Mumbai, Delhi, Bengaluru, Chennai, Kolkata and across India. Kim reviews NGS panels, Guardant360 and FoundationOne reports, explains whether broader DNA or RNA testing is worth doing, and searches trials in India and internationally.
What Kim reviews
- Pathology and tumor profiling (NGS) reports, including FoundationOne, Caris, Tempus and Guardant360
- Signatera and other ctDNA results
- Clinical trials that fit your molecular profile, locally and internationally
- Written questions and evidence your oncologist can act on
Price and scheduling
Every engagement starts with a free 15-minute call. No records or payment needed, and no obligation. The Clarity Report is USD $2,000 (about ₹167,000). Active Case Management: $4,500 / month; Concierge Advisory: $7,500 / month.
Video calls in IST. Paid receipts are suitable for private international policies and select Indian insurers where out-of-network review is covered.
All fees are in US dollars and payable online by card. Calls are scheduled to fit your time zone. Records in languages other than English may require translation before review.
Calls are with Kim Lockheimer, PhD, DFM, Chief Scientific Officer. Prices in local currency: /in/pricing.
Advisory only: diagnosis and treatment stay with your treating oncologist.
NGS testing for cancer in India: what it covers and what it can miss
Next-generation sequencing (NGS) looks for changes in tumor DNA that can point to targeted treatments or clinical trials. In India, panels range from small hotspot tests covering a handful of genes to comprehensive panels covering several hundred. A negative result on a small panel does not always mean there is nothing actionable.
Common gaps include gene fusions (such as ALK, ROS1, RET and NTRK) that are detected more reliably with RNA testing, too little tumor tissue in the sample, and markers like PD-L1, MSI or tumor mutational burden that were never ordered. A blood-based test such as Guardant360 can sometimes help when tissue is limited.
Kim reviews the report you already have, checks which genes and test types were included, and tells you plainly whether broader DNA or RNA testing is likely to change the options your oncologist can consider.
Lung cancer in India: EGFR, immunotherapy and the questions to ask
EGFR mutations are found more often in lung adenocarcinoma among patients in Asia, including India, than in many Western populations. When an EGFR mutation is present, targeted tablets are usually considered before immunotherapy, so knowing the full test result first matters.
Immunotherapy can help some patients with lung cancer, and PD-L1 testing is one factor in that decision. It is generally less helpful for tumors driven by EGFR or ALK changes. Families often ask whether chemotherapy, targeted therapy, immunotherapy or a combination fits their situation; the answer depends on the complete molecular profile.
Useful questions for your oncologist: Was the tumor tested for EGFR, ALK, ROS1, RET, MET, KRAS, BRAF, HER2 and NTRK? Was RNA testing done? What is the PD-L1 result? Are there trials in India or abroad that fit these results? For HER2-positive breast cancer, ask which HER2-directed options are available and whether the HER2 level was confirmed.
Guides for patients
- FoundationOne report explained
- How to read Signatera test results
- Focused Report Review: one report, one question